Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth

Journal of Medicinal Chemistry

Volumn 59, Issue 19, 2016, Pages 8685-8711

  Pérez Pérez, María Jesús ^a   Priego, Eva María ^a   Bueno, Oskía ^a   Martins, Maria Solange ^b   Canela, María Dolores ^a   Liekens, Sandra ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COLCHICINE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; TUBULIN; VASCULAR TARGETING AGENT; ANTINEOPLASTIC AGENT; BIBENZYL DERIVATIVE; COMBRETASTATIN; TUBULIN MODULATOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; CELL DEATH; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; METASTASIS INHIBITION; MICROTUBULE; MITOSIS INHIBITION; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR VASCULARIZATION; VASCULAR DISRUPTING ACTIVITY; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HEMODYNAMICS; METABOLISM; MOLECULAR MODEL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; DRUG DISCOVERY; HEMODYNAMICS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN; TUBULIN MODULATORS;

EID: 84991409677     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00463     Document Type: Review

References (204)

1. Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marmé, D.; LoRusso, P. M. Differentiation and definition of vascular-targeted therapies Clin. Cancer Res. 2005, 11, 416-420
2. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels Nat. Rev. Cancer 2005, 5, 423-435 10.1038/nrc1628
3. Kanthou, C.; Tozer, G. M. Selective destruction of the tumour vasculature by targeting the endothelial cytoskeleton Drug Discovery Today: Ther. Strategies 2007, 4, 237-243 10.1016/j.ddstr.2008.03.003
4. Potente, M.; Gerhardt, H.; Carmeliet, P. Basic and therapeutic aspects of angiogenesis Cell 2011, 146, 873-887 10.1016/j.cell.2011.08.039
5. Carmeliet, P. Angiogenesis in life, disease and medicine Nature 2005, 438, 932-936 10.1038/nature04478
6. El-Kenawi, A. E.; El-Remessy, A. B. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales Br. J. Pharmacol. 2013, 170, 712-729 10.1111/bph.12344
7. Vasudev, N. S.; Reynolds, A. R. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions Angiogenesis 2014, 17, 471-494 10.1007/s10456-014-9420-y
8. Siemann, D. W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents Cancer Treat. Rev. 2011, 37, 63-74 10.1016/j.ctrv.2010.05.001
9. Siemann, D. W.; Horsman, M. R. Modulation of the tumor vasculature and oxygenation to improve therapy Pharmacol. Ther. 2015, 153, 107-124 10.1016/j.pharmthera.2015.06.006
10. Kanthou, C.; Tozer, G. M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies Int. J. Exp. Pathol. 2009, 90, 284-294 10.1111/j.1365-2613.2009.00651.x
11. Thorpe, P. E. Vascular targeting agents as cancer therapeutics Clin. Cancer Res. 2004, 10, 415-427 10.1158/1078-0432.CCR-0642-03
12. Gaya, A. M.; Rustin, G. J. S. Vascular disrupting agents: a new class of drug in cancer therapy Clin. Oncol. 2005, 17, 277-290 10.1016/j.clon.2004.11.011
13. Lara, P. N.; Douillard, J. Y.; Nakagawa, K.; von Pawel, J. v.; McKeage, M. J.; Albert, I.; Losonczy, G.; Reck, M.; Heo, D.-S.; Fan, X.; Fandi, A.; Scagliotti, G. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J. Clin. Oncol. 2011, 29, 2965-2971 10.1200/JCO.2011.35.0660
14. LoRusso, P. M.; Boerner, S. A.; Hunsberger, S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J. Clin. Oncol. 2011, 29, 2952-2955 10.1200/JCO.2011.36.1311
15. Kretzschmann, V.; Fürst, R. Plant-derived vascular disrupting agents: compounds, actions, and clinical trials Phytochem. Rev. 2014, 13, 191-206 10.1007/s11101-013-9304-6
16. Risinger, A. L.; Giles, F. J.; Mooberry, S. L. Microtubule dynamics as a target in oncology Cancer Treat. Rev. 2009, 35, 255-261 10.1016/j.ctrv.2008.11.001
17. Shelanski, M. L.; Taylor, E. W. Properties of the protein subunit of central-pair and outer-doublet microtubules of sea urchin flagella J. Cell Biol. 1968, 38, 304-315 10.1083/jcb.38.2.304
18. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 2004, 428, 198-202 10.1038/nature02393
19. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin Med. Res. Rev. 2008, 28, 155-183 10.1002/med.20097
20. Leung, Y. Y.; Hui, L. L. Y.; Kraus, V. B. Colchicine-Update on mechanisms of action and therapeutic uses Semin. Arthritis Rheum. 2015, 45, 341-350 10.1016/j.semarthrit.2015.06.013
21. Pettit, G. R.; Cragg, G. M.; Singh, S. B. Antineoplastic agents 122. Constituents of Combretum caffrum J. Nat. Prod. 1987, 50, 386-391 10.1021/np50051a008
22. Pettit, G. R.; Temple, C. J.; Narayanan, V. L.; Varma, R.; Simpson, M. J.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs Anti-Cancer Drug Des. 1995, 10, 299-309
23. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 1989, 28, 6984-6991 10.1021/bi00443a031
24. Dark, G. G.; Hill, S. A.; Prise, V. E.; Tozer, G. M.; Pettit, G. R.; Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res. 1997, 57, 1829-1834
25. Greene, L. M.; Meegan, M. J.; Zisterer, D. M. Combretastatins: more than just vascular targeting agents? J. Pharmacol. Exp. Ther. 2015, 355, 212-227 10.1124/jpet.115.226225
26. Mita, M. M.; Sargsyan, L.; Mita, A. C.; Spear, M. Vascular-disrupting agents in oncology Expert Opin. Invest. Drugs 2013, 22, 317-328 10.1517/13543784.2013.759557
27. Porcu, E.; Bortolozzi, R.; Basso, G.; Viola, G. Recent advances in vascular disrupting agents in cancer therapy Future Med. Chem. 2014, 6, 1485-1498 10.4155/fmc.14.104
28. Ji, Y. T.; Liu, Y. N.; Liu, Z. P. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments Curr. Med. Chem. 2015, 22, 1348-1360 10.2174/0929867322666150114163732
29. Barbier, P.; Tsvetkov, P. O.; Breuzard, G.; Devred, F. Deciphering the molecular mechanisms of anti-tubulin plant derived drugs Phytochem. Rev. 2014, 13, 157-169 10.1007/s11101-013-9302-8
30. Tsvetkov, P. O.; Barbier, P.; Breuzard, G.; Peyrot, V.; Devred, F. Microtubule-associated proteins and tubulin interaction by isothermal titration calorimetry. In Methods in Cell Biology; John, J. C.; Leslie, W., Eds.; Academic Press: New York, 2013; Vol. 115, pp 283-302.
31. Fortin, S.; Lacroix, J.; Côté, M. F.; Moreau, E.; Petitclerc, é.; C.-Gaudreault, R. Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site Biol. Proced. Online 2010, 12, 113-117 10.1007/s12575-010-9029-5
32. Canela, M. D.; Pérez-Pérez, M. J.; Noppen, S.; Sáez-Calvo, G.; Díaz, J. F.; Camarasa, M. J.; Liekens, S.; Priego, E. M. Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach J. Med. Chem. 2014, 57, 3924-3938 10.1021/jm401939g
33. Canela, M. D.; Bueno, O.; Noppen, S.; Sáez Calvo, G.; Estévez Gallego, J.; Díaz, J. F.; Camarasa, M. J.; Liekens, S.; Pérez-Pérez, M. J.; Priego, E. M. Targeting the colchicine site in tubulin through cyclohexanedione derivatives RSC Adv. 2016, 6, 19492-19506 10.1039/C5RA26807A
34. Hadimani, M. B.; MacDonough, M. T.; Ghatak, A.; Strecker, T. E.; Lopez, R.; Sriram, M.; Nguyen, B. L.; Hall, J. J.; Kessler, R. J.; Shirali, A. R.; Liu, L.; Garner, C. M.; Pettit, G. R.; Hamel, E.; Chaplin, D. J.; Mason, R. P.; Trawick, M. L.; Pinney, K. G. Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling Combretastatin A-4 with application as a vascular disrupting agent J. Nat. Prod. 2013, 76, 1668-1678 10.1021/np400374w
35. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044 10.1021/jm0512903
36. Lu, Y.; Chen, J.; Xiao, M.; Li, W.; Miller, D. D. An overview of tubulin inhibitors that interact with the colchicine binding site Pharm. Res. 2012, 29, 2943-2971 10.1007/s11095-012-0828-z
37. Shan, Y. S.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y. Developments of combretastatin A-4 derivatives as anticancer agents Curr. Med. Chem. 2011, 18, 523-538 10.2174/092986711794480221
38. Marrelli, M.; Conforti, F.; Statti, G. A.; Cachet, X.; Michel, S.; Tillequin, F.; Menichini, F. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin A-4 Curr. Med. Chem. 2011, 18, 3035-3081 10.2174/092986711796391642
39. Patil, P. O.; Patil, A. G.; Rane, R. A.; Patil, P. C.; Deshmukh, P. K.; Bari, S. B.; Patil, D. A.; Naphade, S. S. Recent advancement in discovery and development of natural product combretastatin-inspired anticancer agents Anti-Cancer Agents Med. Chem. 2015, 15, 955-969 10.2174/1871520615666150526141259
40. Rajak, H.; Kumar Dewangan, P.; Patel, V.; Kumar Jain, D.; Singh, A.; Veerasamy, R.; Chander Sharma, P.; Dixit, A. Design of combretastatin A-4 analogs as tubulin targeted vascular disrupting agent with special emphasis on their cis-restricted isomers Curr. Pharm. Des. 2013, 19, 1923-1955 10.2174/1381612811319100013
41. Kaur, R.; Kaur, G.; Gill, R. K.; Soni, R.; Bariwal, J. Recent developments in tubulin polymerization inhibitors: An overview Eur. J. Med. Chem. 2014, 87, 89-124 10.1016/j.ejmech.2014.09.051
42. álvarez, R.; Medarde, M.; Peláez, R. New ligands of the tubulin colchicine site based on X-ray structures Curr. Top. Med. Chem. 2014, 14, 2231-2252 10.2174/1568026614666141130092637
43. Massarotti, A.; Coluccia, A.; Silvestri, R.; Sorba, G.; Brancale, A. The tubulin colchicine domain: a molecular modeling perspective ChemMedChem 2012, 7, 33-42 10.1002/cmdc.201100361
44. Hartley, R. M.; Peng, J.; Fest, G. A.; Dakshanamurthy, S.; Frantz, D. E.; Brown, M. L.; Mooberry, S. L. Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site Mol. Pharmacol. 2012, 81, 431-439 10.1124/mol.111.075838
45. Jordan, M. A.; Wilson, L. Microtubules as target for anticancer drugs Nat. Rev. Cancer 2004, 4, 253-265 10.1038/nrc1317
46. Pettit, G. R.; Singh, S. B.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Schmidt, J. M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6 J. Med. Chem. 1995, 38, 1666-1672 10.1021/jm00010a011
47. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Chaplin, D. J.; Stratford, M. R. L.; Hamel, E.; Pettit, R. K.; Chapuis, J. C.; Oliva, D. Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug Anti-Cancer Drug Des. 1998, 13, 981-993
48. Pettit, G. R.; Lippert, J. W. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs Anti-Cancer Drug Des. 2000, 15, 203-216
49. Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga, Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novel combretastatin analogues effective against murine solid tumors: Design and structure-activity relationships J. Med. Chem. 1998, 41, 3022-3032 10.1021/jm980101w
50. Folkes, L. K.; Christlieb, M.; Madej, E.; Stratford, M. R. L.; Wardman, P. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals Chem. Res. Toxicol. 2007, 20, 1885-1894 10.1021/tx7002195
51. Ohsumi, K.; Hatanaka, T.; Fujita, K.; Nakagawa, R.; Fukuda, Y.; Nihei, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-Membered heterocyclic analogues Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158 10.1016/S0960-894X(98)00579-4
52. Romagnoli, R.; Baraldi, P. G.; Brancale, A.; Ricci, A.; Hamel, E.; Bortolozzi, R.; Basso, G.; Viola, G. Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents J. Med. Chem. 2011, 54, 5144-5153 10.1021/jm200392p
53. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y.-H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation J. Med. Chem. 2002, 45, 1697-1711 10.1021/jm010523x
54. Zhang, Q.; Peng, Y.; Wang, X. I.; Keenan, S. M.; Arora, S.; Welsh, W. J. Highly potent triazole-based tubulin polymerization inhibitors J. Med. Chem. 2007, 50, 749-754 10.1021/jm061142s
55. Arora, S.; Wang, X. I.; Keenan, S. M.; Andaya, C.; Zhang, Q.; Peng, Y.; Welsh, W. J. Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity Cancer Res. 2009, 69, 1910-1915 10.1158/0008-5472.CAN-08-0877
56. Sun, L.; Vasilevich, N. I.; Fuselier, J. A.; Hocart, S. J.; Coy, D. H. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design Bioorg. Med. Chem. Lett. 2004, 14, 2041-2046 10.1016/j.bmcl.2004.02.050
57. O'Boyle, N. M.; Carr, M.; Greene, L. M.; Bergin, O.; Nathwani, S. M.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents J. Med. Chem. 2010, 53, 8569-8584 10.1021/jm101115u
58. Greene, T. F.; Wang, S.; Greene, L. M.; Nathwani, S. M.; Pollock, J. K.; Malebari, A. M.; McCabe, T.; Twamley, B.; O'Boyle, N. M.; Zisterer, D. M.; Meegan, M. J. Synthesis and biochemical evaluation of 3-phenoxy-1,4-diarylazetidin-2-ones as tubulin-targeting antitumor agents J. Med. Chem. 2016, 59, 90-113 10.1021/acs.jmedchem.5b01086
59. Jiang, J.; Zheng, C.; Zhu, K.; Liu, J.; Sun, N.; Wang, C.; Jiang, H.; Zhu, J.; Luo, C.; Zhou, Y. Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity J. Med. Chem. 2015, 58, 2538-2546 10.1021/acs.jmedchem.5b00118
60. Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic agents. 379. Synthesis of phenstatin phosphate1a J. Med. Chem. 1998, 41, 1688-1695 10.1021/jm970644q
61. Lee, J.; Kim, S. J.; Choi, H.; Kim, Y. H.; Lim, I. T.; Yang, H.-m.; Lee, C. S.; Kang, H. R.; Ahn, S. K.; Moon, S. K.; Kim, D.-H.; Lee, S.; Choi, N. S.; Lee, K. J. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors J. Med. Chem. 2010, 53, 6337-6354 10.1021/jm1002414
62. Oh, D. Y.; Kim, T. M.; Han, S. W.; Shin, D. Y.; Lee, Y. G.; Lee, K. W.; Kim, J. H.; Kim, T. Y.; Jang, I. J.; Lee, J. S.; Bang, Y. J. Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors Cancer Res. Treat. 2016, 48, 28-36 10.4143/crt.2014.258
63. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo Cancer Res. 2004, 64, 4621-4628 10.1158/0008-5472.CAN-03-3474
64. Tung, Y. S.; Coumar, M. S.; Wu, Y. S.; Shiao, H. Y.; Chang, J. Y.; Liou, J. P.; Shukla, P.; Chang, C. W.; Chang, C. Y.; Kuo, C. C.; Yeh, T. K.; Lin, C. Y.; Wu, J. S.; Wu, S. Y.; Liao, C. C.; Hsieh, H. P. Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents J. Med. Chem. 2011, 54, 3076-3080 10.1021/jm101027s
65. Flynn, B. L.; Gill, G. S.; Grobelny, D. W.; Chaplin, J. H.; Paul, D.; Leske, A. F.; Lavranos, T. C.; Chalmers, D. K.; Charman, S. A.; Kostewicz, E.; Shackleford, D. M.; Morizzi, J.; Hamel, E.; Jung, M. K.; Kremmidiotis, G. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties J. Med. Chem. 2011, 54, 6014-6027 10.1021/jm200454y
66. Kremmidiotis, G.; Leske, A. F.; Lavranos, T. C.; Beaumont, D.; Gasic, J.; Hall, A.; O'Callaghan, M.; Matthews, C. A.; Flynn, B. BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy Mol. Cancer Ther. 2010, 9, 1562-1573 10.1158/1535-7163.MCT-09-0815
67. Nien, C. Y.; Chen, Y. C.; Kuo, C. C.; Hsieh, H. P.; Chang, C. Y.; Wu, J. S.; Wu, S. Y.; Liou, J. P.; Chang, J. Y. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors J. Med. Chem. 2010, 53, 2309-2313 10.1021/jm900685y
68. Wen, Z.; Xu, J.; Wang, Z.; Qi, H.; Xu, Q.; Bai, Z.; Zhang, Q.; Bao, K.; Wu, Y.; Zhang, W. 3-(3,4,5-Trimethoxyphenylselenyl)-1H-indoles and their selenoxides as combretastatin A-4 analogs: Microwave-assisted synthesis and biological evaluation Eur. J. Med. Chem. 2015, 90, 184-194 10.1016/j.ejmech.2014.11.024
69. Romagnoli, R.; Baraldi, P. G.; Salvador, M. K.; Prencipe, F.; Lopez-Cara, C.; Schiaffino Ortega, S.; Brancale, A.; Hamel, E.; Castagliuolo, I.; Mitola, S.; Ronca, R.; Bortolozzi, R.; Porcù, E.; Basso, G.; Viola, G. Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin J. Med. Chem. 2015, 58, 3209-3222 10.1021/acs.jmedchem.5b00155
70. La Regina, G.; Bai, R.; Coluccia, A.; Famiglini, V.; Pelliccia, S.; Passacantilli, S.; Mazzoccoli, C.; Ruggieri, V.; Verrico, A.; Miele, A.; Monti, L.; Nalli, M.; Alfonsi, R.; Di Marcotullio, L.; Gulino, A.; Ricci, B.; Soriani, A.; Santoni, A.; Caraglia, M.; Porto, S.; Da Pozzo, E.; Martini, C.; Brancale, A.; Marinelli, L.; Novellino, E.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Bigogno, C.; Dondio, G.; Hamel, E.; Lavia, P.; Silvestri, R. New indole tubulin assembly inhibitors cause stable arrest of mitotic progression, enhanced stimulation of natural killer cell cytotoxic activity, and repression of Hedgehog-dependent cancer J. Med. Chem. 2015, 58, 5789-5807 10.1021/acs.jmedchem.5b00310
71. álvarez, R.; Puebla, P.; Díaz, J. F.; Bento, A. C.; García-Navas, R.; de la Iglesia-Vicente, J.; Mollinedo, F.; Andreu, J. M.; Medarde, M.; Peláez, R. Endowing indole-based tubulin inhibitors with an anchor for derivatization: highly potent 3-substituted indolephenstatins and indoleisocombretastatins J. Med. Chem. 2013, 56, 2813-2827 10.1021/jm3015603
72. Lu, Y.; Li, C. M.; Wang, Z.; Chen, J.; Mohler, M. L.; Li, W.; Dalton, J. T.; Miller, D. D. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl- thiazoles analogues as potent and orally bioavailable anticancer agents J. Med. Chem. 2011, 54, 4678-4693 10.1021/jm2003427
73. La Regina, G.; Bai, R.; Coluccia, A.; Famiglini, V.; Pelliccia, S.; Passacantilli, S.; Mazzoccoli, C.; Ruggieri, V.; Sisinni, L.; Bolognesi, A.; Rensen, W. M.; Miele, A.; Nalli, M.; Alfonsi, R.; Di Marcotullio, L.; Gulino, A.; Brancale, A.; Novellino, E.; Dondio, G.; Vultaggio, S.; Varasi, M.; Mercurio, C.; Hamel, E.; Lavia, P.; Silvestri, R. New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including Hedgehog-dependent cancer J. Med. Chem. 2014, 57, 6531-6552 10.1021/jm500561a
74. Romagnoli, R.; Baraldi, P. G.; Salvador, M. K.; Prencipe, F.; Bertolasi, V.; Cancellieri, M.; Brancale, A.; Hamel, E.; Castagliuolo, I.; Consolaro, F.; Porcù, E.; Basso, G.; Viola, G. Synthesis, antimitotic and antivascular activity of 1-(3′,4′,5′-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles J. Med. Chem. 2014, 57, 6795-6808 10.1021/jm5008193
75. León-González, A. J.; Acero, N.; Muñoz-Mingarro, D.; Navarro, I.; Martín-Cordero, C. Chalcones as promising lead compounds on cancer therapy Curr. Med. Chem. 2015, 22, 3407-3425 10.2174/0929867322666150729114829
76. Ducki, S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly Anti-Cancer Agents Med. Chem. 2009, 9, 336-347 10.2174/1871520610909030336
77. Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Chabert, J. F. D.; McGown, A. T.; Lawrence, N. J. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity Bioorg. Med. Chem. 2009, 17, 7698-7710 10.1016/j.bmc.2009.09.039
78. Zhu, C.; Zuo, Y.; Wang, R.; Liang, B.; Yue, X.; Wen, G.; Shang, N.; Huang, L.; Chen, Y.; Du, J.; Bu, X. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence J. Med. Chem. 2014, 57, 6364-6382 10.1021/jm500024v
79. Martel-Frachet, V.; Keramidas, M.; Nurisso, A.; DeBonis, S.; Rome, C.; Coll, J. L.; Boumendjel, A.; Skoufias, D. A.; Ronot, X. IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma Oncotarget 2015, 6, 14669-14686 10.18632/oncotarget.4144
80. Zheng, S.; Zhong, Q.; Mottamal, M.; Zhang, Q.; Zhang, C.; LeMelle, E.; McFerrin, H.; Wang, G. Design, synthesis, and biological evaluation of novel pyridine-bridged analogues of combretastatin-A4 as anticancer agents J. Med. Chem. 2014, 57, 3369-3381 10.1021/jm500002k
81. Yoshimatsu, K.; Yamaguchi, A.; Yoshino, H.; Koyanagi, N.; Kitoh, K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin Cancer Res. 1997, 57, 3208-3213
82. Hande, K. R.; Hagey, A.; Berlin, J.; Cai, Y.; Meek, K.; Kobayashi, H.; Lockhart, A. C.; Medina, D.; Sosman, J.; Gordon, G. B.; Rothenberg, M. L. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study Clin. Cancer Res. 2006, 12, 2834-2840 10.1158/1078-0432.CCR-05-2159
83. Dorléans, A.; Gigant, B.; Ravelli, R. B.; Mailliet, P.; Mikol, V.; Knossow, M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13775-13779 10.1073/pnas.0904223106
84. Chang, J. Y.; Hsieh, H. P.; Chang, C. Y.; Hsu, K. S.; Chiang, Y. F.; Chen, C. M.; Kuo, C. C.; Liou, J. P. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents J. Med. Chem. 2006, 49, 6656-6659 10.1021/jm061076u
85. Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S. T. C. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent Anti-Cancer Drugs 2006, 17, 25-31 10.1097/01.cad.0000182745.01612.8a
86. Yamazaki, Y.; Sumikura, M.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Anti-microtubule "plinabulin' chemical probe KPU-244-B3 labeled both α- and β-tubulin Bioorg. Med. Chem. 2010, 18, 3169-3174 10.1016/j.bmc.2010.03.037
87. Yamazaki, Y.; Kido, Y.; Hidaka, K.; Yasui, H.; Kiso, Y.; Yakushiji, F.; Hayashi, Y. Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole Bioorg. Med. Chem. 2011, 19, 595-602 10.1016/j.bmc.2010.10.055
88. Wang, Y.; Zhang, H.; Gigant, B.; Yu, Y.; Wu, Y.; Chen, X.; Lai, Q.; Yang, Z.; Chen, Q.; Yang, J. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery FEBS J. 2016, 283, 102-111 10.1111/febs.13555
89. Yamazaki, Y.; Tanaka, K.; Nicholson, B.; Deyanat-Yazdi, G.; Potts, B.; Yoshida, T.; Oda, A.; Kitagawa, T.; Orikasa, S.; Kiso, Y.; Yasui, H.; Akamatsu, M.; Chinen, T.; Usui, T.; Shinozaki, Y.; Yakushiji, F.; Miller, B. R.; Neuteboom, S.; Palladino, M.; Kanoh, K.; Lloyd, G. K.; Hayashi, Y. Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure J. Med. Chem. 2012, 55, 1056-1071 10.1021/jm2009088
90. Reddy, G. R.; Kuo, C.-C.; Tan, U.-K.; Coumar, M. S.; Chang, C.-Y.; Chiang, Y.-K.; Lai, M.-J.; Yeh, J.-Y.; Wu, S.-Y.; Chang, J.-Y.; Liou, J.-P.; Hsieh, H.-P. Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents J. Med. Chem. 2008, 51, 8163-8167 10.1021/jm8008635
91. Burns, C. J.; Harte, M. F.; Bu, X.; Fantino, E.; Joffe, M.; Sikanyika, H.; Su, S.; Tranberg, C. E.; Wilson, N.; Charman, S. A.; Shackleford, D. M.; Wilks, A. F. Discovery of CYT997: a structurally novel orally active microtubule targeting agent Bioorg. Med. Chem. Lett. 2009, 19, 4639-4642 10.1016/j.bmcl.2009.06.079
92. Burns, C. J.; Fantino, E.; Phillips, I. D.; Su, S.; Harte, M. F.; Bukczynska, P. E.; Frazzetto, M.; Joffe, M.; Kruszelnicki, I.; Wang, B.; Wang, Y.; Wilson, N.; Dilley, R. J.; Wan, S. S.; Charman, S. A.; Shackleford, D. M.; Fida, R.; Malcontenti-Wilson, C.; Wilks, A. F. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo Mol. Cancer Ther. 2009, 8, 3036-3045 10.1158/1535-7163.MCT-09-0076
93. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity Cancer Res. 2001, 61, 392-399
94. Oostendorp, R. L.; Witteveen, P. O.; Schwartz, B.; Vainchtein, L. D.; Schot, M.; Nol, A.; Rosing, H.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. M. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors Invest. New Drugs 2010, 28, 163-170 10.1007/s10637-009-9244-6
95. Colley, H. E.; Muthana, M.; Danson, S. J.; Jackson, L. V.; Brett, M. L.; Harrison, J.; Coole, S. F.; Mason, D. P.; Jennings, L. R.; Wong, M.; Tulasi, V.; Norman, D.; Lockey, P. M.; Williams, L.; Dossetter, A. G.; Griffen, E. J.; Thompson, M. J. An orally bioavailable, indole-3-glyoxylamide based series of tubulin polymerization inhibitors showing tumor growth inhibition in a mouse xenograft model of head and neck cancer J. Med. Chem. 2015, 58, 9309-9333 10.1021/acs.jmedchem.5b01312
96. Ricart, A. D.; Ashton, E. A.; Cooney, M. M.; Sarantopoulos, J.; Brell, J. M.; Feldman, M. A.; Ruby, K. E.; Matsuda, K.; Munsey, M. S.; Medina, G.; Zambito, A.; Tolcher, A. W.; Remick, S. C. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors Cancer Chemother. Pharmacol. 2011, 68, 959-970 10.1007/s00280-011-1565-4
97. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps Cancer Res. 2007, 67, 5865-5871 10.1158/0008-5472.CAN-07-0127
98. Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M. B.; Mather, G.; Pleiman, C. M.; Kasibhatla, S.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of N-(4-methoxyphenyl)-N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration J. Med. Chem. 2009, 52, 2341-2351 10.1021/jm801315b
99. Canela, M. D.; Liekens, S.; Camarasa, M. J.; Priego, E. M.; Pérez-Pérez, M. J. Synthesis and antiproliferative activity of 6-phenylaminopurines Eur. J. Med. Chem. 2014, 87, 421-428 10.1016/j.ejmech.2014.09.093
100. Gangjee, A.; Zhao, Y.; Lin, L.; Raghavan, S.; Roberts, E. G.; Risinger, A. L.; Hamel, E.; Mooberry, S. L. Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance J. Med. Chem. 2010, 53, 8116-8128 10.1021/jm101010n
101. Zhang, X.; Raghavan, S.; Ihnat, M.; Thorpe, J. E.; Disch, B. C.; Bastian, A.; Bailey-Downs, L. C.; Dybdal-Hargreaves, N. F.; Rohena, C. C.; Hamel, E.; Mooberry, S. L.; Gangjee, A. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2, 3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents Bioorg. Med. Chem. 2014, 22, 3753-3772 10.1016/j.bmc.2014.04.049
102. D'Amato, R. J.; Lin, C. M.; Flynn, E.; Folkman, J.; Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 3964-3968 10.1073/pnas.91.9.3964
103. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M. J.; Potter, B. V. L. 2-Substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity J. Med. Chem. 2006, 49, 7683-7696 10.1021/jm060705x
104. Stengel, C.; Newman, S. P.; Leese, M. P.; Thomas, M. P.; Potter, B. V. L; Reed, M. J.; Purohit, A.; Foster, P. A. The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by HIF-1 alpha and CAIX expression Anticancer Res. 2015, 35, 5249-5262
105. Leese, M. P.; Jourdan, F.; Dohle, W.; Kimberley, M. R.; Thomas, M. P.; Bai, R.; Hamel, E.; Ferrandis, E.; Potter, B. V. L. Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors ACS Med. Chem. Lett. 2012, 3, 5-9 10.1021/ml200232c
106. Pasquier, E.; Sinnappan, S.; Munoz, M. A.; Kavallaris, M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties Mol. Cancer Ther. 2010, 9, 1408-1418 10.1158/1535-7163.MCT-09-0894
107. Nogales, E.; Wolf, S. G.; Downing, K. H. Structure of the αβ tubulin dimer by electron crystallography Nature 1998, 391, 199-203 10.1038/34465
108. Löwe, J.; Li, H.; Downing, K. H.; Nogales, E. Refined structure of α,β-tubulin at 3.5 Å resolution J. Mol. Biol. 2001, 313, 1045-1057 10.1006/jmbi.2001.5077
109. Janke, C. The tubulin code Molecular components, readout mechanisms, and functions J. Cell Biol. 2014, 206, 461-472 10.1083/jcb.201406055
110. Gigant, B.; Curmi, P. A.; Martin-Barbey, C.; Charbaut, E.; Lachkar, S.; Lebeau, L.; Siavoshian, S.; Sobel, A.; Knossow, M. The 4 Å X-Ray structure of a tubulin:stathmin-like domain complex Cell 2000, 102, 809-816 10.1016/S0092-8674(00)00069-6
111. Barbier, P.; Dorléans, A.; Devred, F.; Sanz, L.; Allegro, D.; Alfonso, C.; Knossow, M.; Peyrot, V.; Andreu, J. M. Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers J. Biol. Chem. 2010, 285, 31672-31681 10.1074/jbc.M110.141929
112. Arce, C. A.; Rodriguez, J. A.; Barra, H. S.; Caputto, R. Incorporation of L-tyrosine, L-phenylalanine and L-3,4-dihydroxyphenylalanine as single units into rat-brain tubulin Eur. J. Biochem. 1975, 59, 145-149 10.1111/j.1432-1033.1975.tb02435.x
113. Prota, A. E.; Magiera, M. M.; Kuijpers, M.; Bargsten, K.; Frey, D.; Wieser, M.; Jaussi, R.; Hoogenraad, C. C.; Kammerer, R. A.; Janke, C.; Steinmetz, M. O. Structural basis of tubulin tyrosination by tubulin tyrosine ligase J. Cell Biol. 2013, 200, 259-270 10.1083/jcb.201211017
114. Prota, A. E.; Bargsten, K.; Zurwerra, D.; Field, J. J.; Diaz, J. F.; Altmann, K.-H.; Steinmetz, M. O. Molecular mechanism of action of microtubule-stabilizing anticancer agents Science 2013, 339, 587-590 10.1126/science.1230582
115. Prota, A. E.; Danel, F.; Bachmann, F.; Bargsten, K.; Buey, R. M.; Pohlmann, J.; Reinelt, S.; Lane, H.; Steinmetz, M. O. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization J. Mol. Biol. 2014, 426, 1848-1860 10.1016/j.jmb.2014.02.005
116. Prota, A. E.; Bargsten, K.; Diaz, J. F.; Marsh, M.; Cuevas, C.; Liniger, M.; Neuhaus, C.; Andreu, J. M.; Altmann, K.-H.; Steinmetz, M. O. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 13817-13821 10.1073/pnas.1408124111
117. McNamara, D. E.; Senese, S.; Yeates, T. O.; Torres, J. Z. Structures of potent anticancer compounds bound to tubulin Protein Sci. 2015, 24, 1164-1172 10.1002/pro.2704
118. Deng, Z.; Chuaqui, C.; Singh, J. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions J. Med. Chem. 2004, 47, 337-344 10.1021/jm030331x
119. Pecqueur, L.; Duellberg, C.; Dreier, B.; Jiang, Q.; Wang, C.; Plueckthun, A.; Surrey, T.; Gigant, B.; Knossow, M. A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 12011-12016 10.1073/pnas.1204129109
120. Ayaz, P.; Ye, X.; Huddleston, P.; Brautigam, C. A.; Rice, L. M. A TOG:alpha beta-tubulin complex structure reveals conformation-based mechanisms for a microtubule polymerase Science 2012, 337, 857-860 10.1126/science.1221698
121. Skoufias, D. A.; Wilson, L. Mechanism of inhibition of microtubule polymerization by colchicine-inhibitory potencies of unliganded colchicine and tubulin colchicine complexes Biochemistry 1992, 31, 738-746 10.1021/bi00118a015
122. Akhmanova, A.; Steinmetz, M. O. Control of microtubule organization and dynamics: two ends in the limelight Nat. Rev. Mol. Cell Biol. 2015, 16, 711-726 10.1038/nrm4084
123. O'Boyle, N. M.; Greene, L. M.; Keely, N. O.; Wang, S.; Cotter, T. S.; Zisterer, D. M.; Meegan, M. J. Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting β-lactam combretastatins Eur. J. Med. Chem. 2013, 62, 705-721 10.1016/j.ejmech.2013.01.016
124. Aprile, S.; Zaninetti, R.; Del Grosso, E.; Genazzani, A. A.; Grosa, G. Metabolic fate of combretastatin A-1: LC-DAD-MS/MS investigation and biological evaluation of its reactive metabolites J. Pharm. Biomed. Anal. 2013, 78-79, 233-242 10.1016/j.jpba.2013.02.030
125. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: design and clinical applications Nat. Rev. Drug Discovery 2008, 7, 255-270 10.1038/nrd2468
126. Eskens, F. A. L. M.; Tresca, P.; Tosi, D.; Van Doorn, L.; Fontaine, H.; Van der Gaast, A.; Veyrat-Follet, C.; Oprea, C.; Hospitel, M.; Dieras, V. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours Br. J. Cancer 2014, 110, 2170-2177 10.1038/bjc.2014.137
127. Nkepang, G.; Bio, M.; Rajaputra, P.; Awuah, S. G.; You, Y. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor Bioconjugate Chem. 2014, 25, 2175-2188 10.1021/bc500376j
128. Yang, T.; Wang, Y.; Li, Z.; Dai, W.; Yin, J.; Liang, L.; Ying, X.; Zhou, S.; Wang, J.; Zhang, X.; Zhang, Q. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature Nanomedicine 2012, 8, 81-92 10.1016/j.nano.2011.05.003
129. Zhang, Y.; Wang, J.; Bian, D.; Zhang, X.; Zhang, Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies Eur. J. Pharm. Biopharm. 2010, 74, 467-473 10.1016/j.ejpb.2010.01.002
130. Zhang, M.; Guo, R.; Wang, Y.; Cao, X.; Shen, M.; Shi, X. Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy Int. J. Nanomed. 2011, 6, 2337-2349 10.2147/IJN.S24705
131. Wang, Y.; Chen, H.; Liu, Y.; Wu, J.; Zhou, P.; Wang, Y.; Li, R.; Yang, X.; Zhang, N. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma Biomaterials 2013, 34, 7181-7190 10.1016/j.biomaterials.2013.05.081
132. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system Nature 2005, 436, 568-572 10.1038/nature03794
133. Poojari, R.; Kini, S.; Srivastava, R.; Panda, D. A chimeric cetuximab-functionalized corona as a potent delivery system for microtubule-destabilizing nanocomplexes to hepatocellular carcinoma cells: a focus on EGFR and tubulin intracellular dynamics Mol. Pharmaceutics 2015, 12, 3908-3923 10.1021/acs.molpharmaceut.5b00337
134. Song, W.; Tang, Z.; Zhang, D.; Yu, H.; Chen, X. Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions Small 2015, 11, 3755-3761 10.1002/smll.201500324
135. Al-Abd, A. M.; Aljehani, Z. K.; Gazzaz, R. W.; Fakhri, S. H.; Jabbad, A. H.; Alahdal, A. M.; Torchilin, V. P. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors J. Controlled Release 2015, 219, 269-277 10.1016/j.jconrel.2015.08.055
136. Tozer, G. M.; Prise, V. E.; Wilso, J.; Cemazar, M.; Shan, S.; Dewhirst, M. W.; Barber, P. R.; Vojnovic, B.; Chaplin, D. J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability Cancer Res. 2001, 61, 6413-6422
137. McPhail, L. D.; Griffiths, J. R.; Robinson, S. P. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging Int. J. Radiat. Oncol., Biol., Phys. 2007, 69, 1238-1245 10.1016/j.ijrobp.2007.08.025
138. Chen, G.; Horsman, M. R.; Pedersen, M.; Pang, Q.; Stødkilde-Jørgensen, H. The effect of combretastatin A4 disodium phosphate and 5,6- dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours Acta Oncol. 2008, 47, 1071-1076 10.1080/02841860701769750
139. Zhao, D.; Richer, E.; Antich, P. P.; Mason, R. P. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI FASEB J. 2008, 22, 2445-2451 10.1096/fj.07-103713
140. Nielsen, T.; Bentzen, L.; Pedersen, M.; Tramm, T.; Rijken, P. F. J. W.; Bussink, J.; Horsman, M. R.; Ostergaard, L. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging Clin. Cancer Res. 2012, 18, 6469-6477 10.1158/1078-0432.CCR-12-2014
141. Horsman, M. R.; Murata, R.; Breidahl, T.; Nielsen, F. U.; Maxwell, R. J.; Stødkiled-Jørgensen, H.; Overgaard, J. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy: Combretastatins and conventional therapy Adv. Exp. Med. Biol. 2000, 476, 311-323 10.1007/978-1-4615-4221-6-26
142. Lunt, S. J.; Akerman, S.; Hill, S. A.; Fisher, M.; Wright, V. J.; Reyes-Aldasoro, C. C.; Tozer, G. M.; Kanthou, C. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate Int. J. Cancer 2011, 129, 1979-1989 10.1002/ijc.25848
143. Ley, C. D.; Horsman, M. R.; Kristjansen, P. E. G. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure Neoplasia 2007, 9, 108-112 10.1593/neo.06733
144. Williams, L. J.; Mukherjee, D.; Fisher, M.; Reyes-Aldasoro, C. C.; Akerman, S.; Kanthou, C.; Tozer, G. M. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate Br. J. Pharmacol. 2014, 171, 4902-4913 10.1111/bph.12817
145. Vincent, L.; Kermani, P.; Young, L. M.; Cheng, J.; Zhang, F.; Shido, K.; Lam, G.; Bompais-Vincent, H.; Zhu, Z.; Hicklin, D. J.; Bohlen, P.; Chaplin, D. J.; May, C.; Rafii, S. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling J. Clin. Invest. 2005, 115, 2992-3006 10.1172/JCI24586
146. Hussain, A.; Steimle, M.; Hoppeler, H.; Baum, O.; Egginton, S. The vascular-disrupting agent combretastatin impairs splitting and sprouting forms of physiological angiogenesis Microcirculation 2012, 19, 296-305 10.1111/j.1549-8719.2012.00160.x
147. Jiang, Z.; Wu, M.; Miao, J.; Duan, H.; Zhang, S.; Chen, M.; Sun, L.; Wang, Y.; Zhang, X.; Zhu, X.; Zhang, L. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects Int. J. Biochem. Cell Biol. 2013, 45, 1710-1719 10.1016/j.biocel.2013.04.030
148. Ahmed, B.; Van Eijk, L. I.; Bouma-ter Steege, J. C. A.; Van Der Schaft, D. W. J.; Van Esch, A. M.; Joosten-Achjanie, S. R.; Lambin, P.; Landuyt, W.; Griffioen, A. W. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity Int. J. Cancer 2003, 105, 20-25 10.1002/ijc.11010
149. Porcù, E.; Viola, G.; Bortolozzi, R.; Persano, L.; Mitola, S.; Ronca, R.; Presta, M.; Romagnoli, R.; Baraldi, P. G.; Basso, G. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis Angiogenesis 2013, 16, 647-662 10.1007/s10456-013-9343-z
150. Samarin, J.; Rehm, M.; Krueger, B.; Waschke, J.; Goppelt-Struebe, M. Up-regulation of connective tissue growth factor in endothelial cells by the microtubule-destabilizing agent combretastatin A-4 Mol. Cancer Res. 2009, 7, 180-188 10.1158/1541-7786.MCR-08-0292
151. Alotaibi, M. R.; Asnake, B.; Di, X.; Beckman, M. J.; Durrant, D.; Simoni, D.; Baruchello, R.; Lee, R. M.; Schwartz, E. L.; Gewirtz, D. A. Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death Biochem. Pharmacol. 2013, 86, 1688-1698 10.1016/j.bcp.2013.10.007
152. Shen, C. H.; Shee, J. J.; Wu, J. Y.; Lin, Y. W.; Wu, J. D.; Liu, Y. W. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model Br. J. Pharmacol. 2010, 160, 2008-2027 10.1111/j.1476-5381.2010.00861.x
153. Kanthou, C.; Greco, O.; Stratford, A.; Cook, I.; Knight, R.; Benzakour, O.; Tozer, G. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death Am. J. Pathol. 2004, 165, 1401-1411 10.1016/S0002-9440(10)63398-6
154. Nabha, S. M.; Mohammad, R. M.; Dandashi, M. H.; Coupaye-Gerard, B.; Aboukameel, A.; Pettit, G. R.; Al-Katib, A. M. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage Clin. Cancer Res. 2002, 8, 2735-2741
155. Vitale, I.; Galluzzi, L.; Castedo, M.; Kroemer, G. Mitotic catastrophe: a mechanism for avoiding genomic instability Nat. Rev. Mol. Cell Biol. 2011, 12, 385-392 10.1038/nrm3115
156. Nabha, S. M.; Wall, N. R.; Mohammad, R. M.; Pettit, G. R.; Al-Katib, A. M. Effects of Combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines Anti-Cancer Drugs 2000, 11, 385-392 10.1097/00001813-200006000-00009
157. Cenciarelli, C.; Tanzarella, C.; Vitale, I.; Pisano, C.; Crateri, P.; Meschini, S.; Arancia, G.; Antoccia, A. The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460 Apoptosis 2008, 13, 659-669 10.1007/s10495-008-0200-2
158. Vitale, I.; Antoccia, A.; Cenciarelli, C.; Crateri, P.; Meschini, S.; Arancia, G.; Pisano, C.; Tanzarella, C. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells Apoptosis 2007, 12, 155-166 10.1007/s10495-006-0491-0
159. O'Boyle, N. M.; Carr, M.; Greene, L. M.; Keely, N. O.; Knox, A. J. S.; McCabe, T.; Lloyd, D. G.; Zisterer, D. M.; Meegan, M. J. Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe Eur. J. Med. Chem. 2011, 46, 4595-4607 10.1016/j.ejmech.2011.07.039
160. Green, D. R.; Llambi, F. Cell death signaling Cold Spring Harbor Perspect. Biol. 2015, 7, a006080 10.1101/cshperspect.a006080
161. Iyer, S.; Chaplin, D. J.; Rosenthal, D. S.; Boulares, A. H.; Li, L. Y.; Smulson, M. E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4 Cancer Res. 1998, 58, 4510-4514
162. Petit, I.; Karajannis, M. A.; Vincent, L.; Young, L.; Butler, J.; Hooper, A. T.; Shido, K.; Steller, H.; Chaplin, D. J.; Feldman, E.; Rafii, S. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood 2008, 111, 1951-1961 10.1182/blood-2007-05-089219
163. Mendez, G.; Policarpi, C.; Cenciarelli, C.; Tanzarella, C.; Antoccia, A. Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison combretastatin-A4 Apoptosis 2011, 16, 940-949 10.1007/s10495-011-0619-8
164. Méndez-Callejas, G. M.; Leone, S.; Tanzarella, C.; Antoccia, A. Combretastatin A-4 induces p53 mitochondrial-relocalisation independent-apoptosis in non-small lung cancer cells Cell Biol. Int. 2014, 38, 296-308 10.1002/cbin.10199
165. Mahal, K.; Ahmad, A.; Sethi, S.; Resch, M.; Ficner, R.; Sarkar, F. H.; Schobert, R.; Biersack, B. Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells Cell. Oncol. 2015, 38, 463-478 10.1007/s13402-015-0243-7
166. Lin, H. L.; Chiou, S. H.; Wu, C. W.; Lin, W. B.; Chen, L. H.; Yang, Y. P.; Tsai, M. L.; Uen, Y. H.; Liou, J. P.; Chi, C. W. Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells J. Pharmacol. Exp. Ther. 2007, 323, 365-373 10.1124/jpet.107.124966
167. Pollock, J. K.; Verma, N. K.; O'Boyle, N. M.; Carr, M.; Meegan, M. J.; Zisterer, D. M. Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway Biochem. Pharmacol. 2014, 92, 544-557 10.1016/j.bcp.2014.10.002
168. Hori, K.; Saito, S.; Kubota, K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs Br. J. Cancer 2002, 86, 1604-1614 10.1038/sj.bjc.6600296
169. Ridley, A. J. Rho GTPase signalling in cell migration Curr. Opin. Cell Biol. 2015, 36, 103-112 10.1016/j.ceb.2015.08.005
170. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells Blood 2002, 99, 2060-2069 10.1182/blood.V99.6.2060
171. Wang, Y.; Wang, B.; Guerram, M.; Sun, L.; Shi, W.; Tian, C.; Zhu, X.; Jiang, Z.; Zhang, L. Deoxypodophyllotoxin suppresses tumor vasculature in HUVECs by promoting cytoskeleton remodeling through LKB1-AMPK dependent Rho A activation Oncotarget 2015, 6, 29497-29512 10.18632/oncotarget.4985
172. Hori, K.; Akita, H.; Nonaka, H.; Sumiyoshi, A.; Taki, Y. Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface Cancer Sci. 2014, 105, 1196-1204 10.1111/cas.12477
173. Yao, N.; Ren, K.; Jiang, C.; Gao, M.; Huang, D.; Lu, X.; Lou, B.; Peng, F.; Yang, A.; Wang, X.; Ni, Y.; Zhang, J. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo Tumor Biol. 2015, 36, 8499-8510 10.1007/s13277-015-3508-x
174. El-Emir, E.; Boxer, G. M.; Petrie, I. A.; Boden, R. W.; Dearling, J. L. J.; Begent, R. H. J.; Pedley, R. B. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice Eur. J. Cancer 2005, 41, 799-806 10.1016/j.ejca.2005.01.001
175. Dachs, G. U.; Steele, A. J.; Coralli, C.; Kanthou, C.; Brooks, A. C.; Gunningham, S. P.; Currie, M. J.; Watson, A. I.; Robinson, B. A.; Tozer, G. M. Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression BMC Cancer 2006, 6, 280 10.1186/1471-2407-6-280
176. Peichev, M.; Naiyer, A. J.; Pereira, D.; Zhu, Z.; Lane, W. J.; Williams, M.; Oz, M. C.; Hicklin, D. J.; Witte, L.; Moore, M. A. S.; Rafii, S. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors Blood 2000, 95, 952-958
177. Nolan, D. J.; Ciarrocchi, A.; Mellick, A. S.; Jaggi, J. S.; Bambino, K.; Gupta, S.; Heikamp, E.; McDevitt, M. R.; Scheinberg, D. A.; Benezra, R.; Mittal, V. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes Dev. 2007, 21, 1546-1558 10.1101/gad.436307
178. Ceradini, D. J.; Kulkarni, A. R.; Callaghan, M. J.; Tepper, O. M.; Bastidas, N.; Kleinman, M. E.; Capla, J. M.; Galiano, R. D.; Levine, J. P.; Gurtner, G. C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 Nat. Med. 2004, 10, 858-864 10.1038/nm1075
179. Moschetta, M.; Mishima, Y.; Sahin, I.; Manier, S.; Glavey, S.; Vacca, A.; Roccaro, A. M.; Ghobrial, I. M. Role of endothelial progenitor cells in cancer progression Biochim. Biophys. Acta, Rev. Cancer 2014, 1846, 26-39 10.1016/j.bbcan.2014.03.005
180. Shaked, Y.; Tang, T.; Woloszynek, J.; Daenen, L. G.; Man, S.; Xu, P.; Cai, S. R.; Arbeit, J. M.; Voest, E. E.; Chaplin, D. J.; Smythe, J.; Harris, A.; Nathan, P.; Judson, I.; Rustin, G.; Bertolini, F.; Link, D. C.; Kerbel, R. S. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents Cancer Res. 2009, 69, 7524-7528 10.1158/0008-5472.CAN-09-0381
181. Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C. R.; Man, S.; Cheung, A. M.; Hicklin, D. J.; Chaplin, D.; Foster, F. S.; Benezra, R.; Kerbel, R. S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 2006, 313, 1785-1787 10.1126/science.1127592
182. Lewis, C. E.; De Palma, M.; Naldini, L. Tie2-expressing monocytes and tumor angiogenesis: Regulation by hypoxia and angiopoietin-2 Cancer Res. 2007, 67, 8429-8432 10.1158/0008-5472.CAN-07-1684
183. Welford, A. F.; Biziato, D.; Coffelt, S. B.; Nucera, S.; Fisher, M.; Pucci, F.; Di Serio, C.; Naldini, L.; De Palma, M.; Tozer, G. M.; Lewis, C. E. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice J. Clin. Invest. 2011, 121, 1969-1973 10.1172/JCI44562
184. Parkins, C. S.; Holder, A. L.; Hill, S. A.; Chaplin, D. J.; Tozer, G. M. Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide Br. J. Cancer 2000, 83, 811-816 10.1054/bjoc.2000.1361
185. Bohn, A. B.; Wittenborn, T.; Brems-Eskildsen, A. S.; Laurberg, T.; Bertelsen, L. B.; Nielsen, T.; Stødkilde-Jørgensen, H.; Møller, B. K.; Horsman, M. R. A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models PLoS One 2014, 9, e110091 10.1371/journal.pone.0110091
186. Greene, L. M.; O'Boyle, N. M.; Nolan, D. P.; Meegan, M. J.; Zisterer, D. M. The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells Biochem. Pharmacol. 2012, 84, 612-624 10.1016/j.bcp.2012.06.005
187. Li, Y.; Luo, P.; Wang, J.; Dai, J.; Yang, X.; Wu, H.; Yang, B.; He, Q. Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway Toxicol. Appl. Pharmacol. 2014, 274, 319-327 10.1016/j.taap.2013.11.018
188. Clémenson, C.; Jouannot, E.; Merino-Trigo, A.; Rubin-Carrez, C.; Deutsch, E. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models Invest. New Drugs 2013, 31, 273-284 10.1007/s10637-012-9852-4
189. Martinelli, M.; Bonezzi, K.; Riccardi, E.; Kuhn, E.; Frapolli, R.; Zucchetti, M.; Ryan, A. J.; Taraboletti, G.; Giavazzi, R. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel Br. J. Cancer 2007, 97, 888-894 10.1038/sj.bjc.6603969
190. Wu, X. Y.; Ma, W.; Gurung, K.; Guo, C. H. Mechanisms of tumor resistance to small-molecule vascular disrupting agents: Treatment and rationale of combination therapy J. Formosan Med. Assoc. 2013, 112, 115-124 10.1016/j.jfma.2012.09.017
191. Nathan, P.; Zweifel, M.; Padhani, A. R.; Koh, D. M.; Ng, M.; Collins, D. J.; Harris, A.; Carden, C.; Smythe, J.; Fisher, N.; Taylor, N. J.; Stirling, J. J.; Lu, S. P.; Leach, M. O.; Rustin, G. J. S.; Judson, I. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer Clin. Cancer Res. 2012, 18, 3428-3439 10.1158/1078-0432.CCR-11-3376
192. Moens, S.; Goveia, J.; Stapor, P. C.; Cantelmo, A. R.; Carmeliet, P. The multifaceted activity of VEGF in angiogenesis-Implications for therapy responses Cytokine Growth Factor Rev. 2014, 25, 473-482 10.1016/j.cytogfr.2014.07.009
193. Lambrechts, D.; Lenz, H. J.; De Haas, S.; Carmeliet, P.; Scherer, S. J. Markers of response for the antiangiogenic agent bevacizumab J. Clin. Oncol. 2013, 31, 1219-1230 10.1200/JCO.2012.46.2762
194. Zweifel, M.; Jayson, G. C.; Reed, N. S.; Osborne, R.; Hassan, B.; Ledermann, J.; Shreeves, G.; Poupard, L.; Lu, S. P.; Balkissoon, J.; Chaplin, D. J.; Rustin, G. J. S. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer Ann. Oncol. 2011, 22, 2036-2041 10.1093/annonc/mdq708
195. Sosa, J. A.; Balkissoon, J.; Lu, S. P.; Langecker, P.; Elisei, R.; Jarzab, B.; Bal, C. S.; Marur, S.; Gramza, A.; Ondrey, F. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer Surgery 2012, 152, 1078-1087 10.1016/j.surg.2012.08.036
196. von Pawel, J.; Gorbounova, V.; Reck, M.; Kowalski, D. M.; Allard, A.; Chadjaa, M.; Rey, A.; Bennouna, J.; Grossi, F. DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer Lung Cancer 2014, 85, 224-229 10.1016/j.lungcan.2014.05.013
197. Siemann, D. W.; Mercer, E.; Lepler, S.; Rojiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int. J. Cancer 2002, 99, 1-6 10.1002/ijc.10316
198. Bilenker, J. H.; Flaherty, K. T.; Rosen, M.; Davis, L.; Gallagher, M.; Stevenson, J. P.; Sun, W.; Vaughn, D.; Giantonio, B.; Zimmer, R.; Schnall, M.; O'Dwyer, P. J. Phase I trial of combretastatin A-4 phosphate with carboplatin Clin. Cancer Res. 2005, 11, 1527-1533 10.1158/1078-0432.CCR-04-1434
199. Brouhard, G. J.; Rice, L. M. The contribution of αβ-tubulin curvature to microtubule dynamics J. Cell Biol. 2014, 207, 323-334 10.1083/jcb.201407095
200. Tozer, G. M.; Prise, V. E.; Wilson, J.; Locke, R. J.; Vojnovic, B.; Stratford, M. R. L.; Dennis, M. F.; Chaplin, D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues Cancer Res. 1999, 59, 1626-1634
201. Kim, C.; Yang, H.; Fukushima, Y.; Saw, P.; Lee, J.; Park, J. S.; Park, I.; Jung, J.; Kataoka, H.; Lee, D.; DoHeo, W.; Kim, I.; Jon, S.; Adams, R. H.; Nishikawa, S. I.; Uemura, A.; Koh, G. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption Cancer Cell 2014, 25, 102-117 10.1016/j.ccr.2013.12.010
202. Quan, H.; Xu, Y.; Lou, L. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4 Int. J. Cancer 2008, 122, 1730-1737 10.1002/ijc.23262
203. Kwon, E. J.; Lo, J. H.; Bhatia, S. N. Smart nanosystems: Bio-inspired technologies that interact with the host environment Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 14460-14466 10.1073/pnas.1508522112
204. Lin, K. Y.; Kwon, E. J.; Lo, J. H.; Bhatia, S. N. Drug-induced amplification of nanoparticle targeting to tumors Nano Today 2014, 9, 550-559 10.1016/j.nantod.2014.09.001